54.09
price down icon0.20%   -0.11
pre-market  プレマーケット:  54.09  
loading

Akero Therapeutics Inc (AKRO) 最新ニュース

pulisher
Nov 03, 2025

How high can Akero Therapeutics Inc. stock goEarnings Trend Report & Daily Growth Stock Tips - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsPortfolio Return Report & AI Powered Market Entry Ideas - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Heatmap analysis for Akero Therapeutics Inc. and competitorsJuly 2025 Patterns & Community Supported Trade Ideas - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunity - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Can Akero Therapeutics Inc. (0K4) stock beat analyst consensusJuly 2025 Movers & Reliable Entry Point Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Will Akero Therapeutics Inc. (0K4) stock rise with strong economyTrade Analysis Report & Real-Time Volume Surge Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is Akero Therapeutics Inc. stock a buy before product launchesWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Will Akero Therapeutics Inc. stock gain from lower inflationTrade Risk Assessment & Precise Entry and Exit Recommendations - newser.com

Nov 03, 2025
pulisher
Nov 02, 2025

Can volume confirm reversal in Akero Therapeutics Inc.GDP Growth & Safe Entry Trade Reports - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

How rising interest rates impact Akero Therapeutics Inc. stockCEO Change & AI Driven Price Predictions - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Can Akero Therapeutics Inc. (0K4) stock surprise with quarterly resultsWeekly Loss Report & Community Driven Trade Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Will Akero Therapeutics Inc. outperform the marketGap Down & Comprehensive Market Scan Insights - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Why Akero Therapeutics Stock Trounced the Market on Thursday - AOL.com

Nov 02, 2025
pulisher
Nov 02, 2025

Using RSI to spot recovery in Akero Therapeutics Inc.Gap Up & Expert Curated Trade Setups - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Chart based analysis of Akero Therapeutics Inc. trendsWeekly Market Outlook & Entry Point Confirmation Signals - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Is Akero Therapeutics Inc. stock a top pick in earnings seasonPortfolio Risk Summary & Technical Entry and Exit Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Jennison Associates LLC Grows Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Will Akero Therapeutics Inc. stock reach Wall Street targetsAnalyst Downgrade & High Conviction Buy Zone Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Y Intercept Hong Kong Ltd Takes Position in Akero Therapeutics, Inc. $AKRO - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Update - MarketBeat

Nov 02, 2025
pulisher
Oct 31, 2025

Fatty liver disease companies' multibillion-dollar deals mean fatter walletsSan Francisco Business Times - The Business Journals

Oct 31, 2025
pulisher
Oct 31, 2025

Is Akero Therapeutics Inc. trending in predictive chart modelsJuly 2025 Levels & Weekly High Return Opportunities - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

Emerald Mutual Fund Advisers Trust Has $7.27 Million Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat

Oct 31, 2025
pulisher
Oct 31, 2025

Is Akero Therapeutics Inc. (0K4) stock included in top ETFsJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

Why Akero Therapeutics Inc. stock is recommended by analystsTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 31, 2025
pulisher
Oct 30, 2025

Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha

Oct 30, 2025
pulisher
Oct 30, 2025

Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant - MSN

Oct 30, 2025
$37.30
price down icon 0.64%
$28.71
price up icon 0.35%
$101.57
price up icon 8.65%
$103.95
price up icon 0.04%
biotechnology ONC
$311.86
price up icon 0.44%
$186.23
price down icon 1.78%
大文字化:     |  ボリューム (24 時間):